A Holistic Approach to Diagnosing Retinal Vein Occlusion

A Holistic Approach to Diagnosing Retinal Vein Occlusion
Media formats available:
Details
Presenters
  • Overview

    To ensure a timely and informed referral, optometrists must be aware of the signs, symptoms, differential diagnosis, and systemic testing associated with retinal vein occlusion (RVO). Drs. Modi, Ferrucci, and Majcher discuss best practices for diagnosing, treating, and managing patients with RVO.  

    This content was captured during a synchronous virtual symposium. Polling took place during the symposium.

    This activity is supported by an unrestricted educational grant from Regeneron Pharmaceuticals, Inc.

     

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Recognize the prevalence and risk factors for retinal vein occlusion (RVO)
    • Describe the signs, symptoms, and imaging tests that can aid in the diagnosis of RVO
    • Review the differential diagnosis for RVO
    • Investigate systemic causes of RVO
    • Develop strategies for improved communication and collaboration with primary care practitioners and ophthalmologists involved in the care of patients with RVO
    • Summarize best practices for treating and managing patients with RVO
    • Accreditation

      Sponsored by  

      Evolve Medical Education LLC (Evolve) is a COPE-accredited administrator. 

      This activity, COPE Activity Number 126543, is accredited by COPE for continuing education for optometrists. This course is approved for 1 hour of CE.

      Course #: 85530-TD
      Activity #: 126543

      COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.

    • Faculty and Disclosures

      Yasha S. Modi, MD, MHS

      Yasha S. Modi, MD, MHS

      Associate Professor of Ophthalmology
      Department of Ophthalmology
      Director of Tele-Retina
      NYU Langone Health
      New York, NY


      Steven Ferrucci, OD, FAAO, FORS

      Steven Ferrucci, OD, FAAO, FORS

      Chief, Optometry, Sepulveda VA
      Professor, Southern California College of Optometry
      Los Angeles, CA


      Carolyn E. Majcher, OD, FAAO, FORS

      Carolyn E. Majcher, OD, FAAO, FORS

      Associate Professor & Director of Residency Programs
      Oklahoma College of Optometry
      Northeastern State University
      Tahlequah, OK


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Yasha S. Modi, MD, MHS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Alimera Sciences, Allergan/AbbVie, Apellis Pharmaceuticals, Carl Zeiss Meditec, DORC, Genentech, Iveric Bio, and Théa Pharma.

      Steven Ferrucci, OD, FAAO, FORS, has had a financial relationship or affiliation with the following ineligible companies in the form of Advisory Board: Apellis Pharmaceuticals, Iveric Bio, Novartis, OcuTerra, ScienceBased Health, and Visible Genomics. Consultant: iCare. Speaker's Bureau: LKC Technologies, Regeneron, and Visionix. 

      Carolyn E. Majcher, OD, FAAO, FORS, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Apellis Pharmaceuticals, Carl Zeiss Meditec, Iveric Bio, LENZ Therapeutics, Notal Vision, OcuTerra, Optomed, and Regeneron. Speaker's Bureau: Carl Zeiss Meditec, Iveric Bio, Optomed, and Regeneron. Nonfinancial support (writing assistance): Roche.

      The Evolve staff, planners, and peer reviewer have no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Regeneron Pharmaceuticals, Inc.

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Release Date:

      Expiration Date:

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free